Lv1
88 积分 2022-08-12 加入
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
2天前
已完结
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
3天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
17天前
已完结
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations
18天前
已完结
Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
1个月前
已完结
Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
1个月前
已关闭
Non-small-cell lung cancer
2个月前
已完结
Cabozantinib for the treatment of hepatocellular carcinoma
3个月前
已完结
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
3个月前
已完结
皖公网安备34019202002308
